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Quantum mechanical methods for drug design
Abstract
Quantum mechanical (QM) methods are becoming popular in computational drug design and
development mainly because high accuracy is required to estimate (relative) binding affinities. For
low-to medium-throughput in silico screening, (e.g., scoring and prioritizing a series of inhibitors
sharing the same molecular scaffold) efficient approximations have been developed in the past decade,
like linear scaling QM in which the computation time scales almost linearly with the number of basis
functions. Furthermore, QM-based procedures have been used recently for determining protonation
states of ionizable groups, evaluating energies, and optimizing molecular structures. For
high-throughput in silico screening QM approaches have been employed to derive robust quantitative
structure-activity relationship models. It is expected that the use of QM methods will keep growing in
all phases of computer-aided drug design and development. However, extensive sampling of
conformational space and treatment of solution of macromolecules are still limiting factors for the broad
application of QM in drug design.
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Abstract
Quantum mechanical (QM) methods are becoming popular in computational drug design
and development mainly because high accuracy is required to estimate (relative) binding affini-
ties. For low- to medium-throughput in silico screening, (e.g., scoring and prioritizing a series
of inhibitors sharing the same molecular scaffold) efficient approximations have been devel-
oped in the past decade, like linear scaling QM in which the computation time scales almost
linearly with the number of basis functions. Furthermore, QM-based procedures have been
used recently for determining protonation states of ionizable groups, evaluating energies, and
optimizing molecular structures. For high-throughput in silico screening QM approaches have
been employed to derive robust quantitative structure-activity relationship models. It is ex-
pected that the use of QM methods will keep growing in all phases of computer-aided drug
design and development. However, extensive sampling of conformational space and treatment
of solution of macromolecules are still limiting factors for the broad application of QM in drug
design.
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Introduction
Accurate models for computing the binding free energy between small molecules and proteins are
needed for drug discovery and design.1 The increasing popularity of quantum mechanical meth-
ods in computer-aided drug design (CADD) is not just a consequence of ever growing computing
power but is also due to the first principle nature of QM, which should provide the highest accu-
racy.2,3 Because of their first principle nature, both the time-consuming ab initio methods4 and
fast semi-empirical approaches5,6 do not suffer from the limitation inherent to the ball and spring
description and the fixed-charge approximation used in the force fields (FFs). In a recent review, it
has been suggested that the application of QM methods in all phases of CADD is likely to become
reality.3 At the same time, interest for QM in CADD has spurred further methodological devel-
opment of QM methods and in particular QM approaches for docking, scoring, improvement of
known lead compounds, and unraveling the reaction mechanism. As an example, QM calculations
were performed to investigate significant differences in binding affinities upon modification of a
−CH2− linker into a carbonyl.7
In the following sections, we will classify the QM methods into two broad classes according
to their functionalities: the first class includes the methods used for quantifying energies and op-
timizing structures, while the second contains the techniques employed for calculating molecular
properties. The methods in the first class are the conventional and straightforward applications of
QM. They can be directly exploited for interpreting the reactivities of biologically active molecules,
which are always accompanied by the transfer of energy and transformation of molecular struc-
tures. However, the currently available computating power is not enough for the direct ab initio
QM calculations of macromolecules with accuracy similar to that of in vitro experiments. There-
fore this section will unavoidably give the prominence to the acceleration of QM methods for
macromolecules, including linear scaling algorithms and hybrid quantum-mechanics/molecular-
mechanics (QM/MM). Apart from the methods for calculating the energies and optimizing struc-
tures of biomolecules, we also illustrate two typical applications of QM relevant to structure-based
drug design: the analysis of the protonation states of titratable side chains8,9 and the evaluation,
with high structural and energetic accuracy, of cation-pi and pi-pi interactions that are beyond the
limits of classical FF methods. The methods in the second class are mainly used for calculating
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specific properties of molecules, such as partial charges, bond strength, and torsion angles which
can be applied in the parameterization of FFs, and other descriptors that can be used in building
quantitative structure-activity relationship (QSAR) models or quantitative structure-property re-
lationship (QSPR) models. We also discuss recent advances in two emerging topics: molecular
quantum similarity and variational particle number approach for molecular design.
Using QM to calculate energies and optimize structures
QM is preferable to classical FF based methods for accurate energies and electronic structure
calculations,2,3 and even for examining the potential energy hypersurface of small molecules.10
Recently, Butler and coworkers used QM-based methods to describe both the internal energy of
the ligand and the solvation effect.11 Their analysis indicates that two thirds of the bioactive con-
formations of small-molecule inhibitors lie within 0.5 kcal·mol−1 of a local minimum, and confor-
mations with penalties above 2.0 kcal·mol−1 are generally attributable to inaccuracies in structure
determination. However QM can only be applied to molecular systems of limited size, so that QM
has to be simplified to adapt to the available computational power, e.g., apply pure QM to a small
subset of atoms and polarizable continuum model to emulate the protein and the solvent,12 or use
accelerated techniques which will be mentioned in the following sections.
Linear scaling QM methods
The computational time of QM ranges from N3 (semi-empirical) to N5 (second order Møller-
Plesset perturbation theory (MP2) and other post-Hartree-Fock (HF) methods), where N is the
number of basis functions.13 Linear scaling quantum mechanics (LSQM) has been applied exten-
sively for the evaluation of binding enthalpy between small molecules and proteins.2,3 In LSQM,
the computing time scales with N2 or even N if the local character of chemical interactions is fully
exploited.14–18 In the divide-and-conquer (D&C) approach, one of the typical LSQM techniques,
a large system is decomposed into many subsystems, and the density matrix of each subsystem
is determined separately. Finally contributions of individual subsystems are summed to obtain
the total density matrix and energy of the system (Figure 1).15–17,19 Raha and Merz developed a
semi-empirical D&C-based scoring function18 and studied the ion-mediated ligand binding pro-
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cess. Their study shows that QM is needed for metal-containing system, because the atom types
and parameters of metal atoms in most classical FFs are not accurate enough to describe the nature
of the interactions between a small molecule and a metal ion in the active site.20
We have suggested the use of a semi-empirical D&C strategy as an improvement of the lin-
ear interaction energy model with continuum electrostatic solvation (LIECE).21 The new method
QMLIECE was compared to LIECE by application to three enzymes belonging to different classes:
the West Nile virus NS3 serine protease (WNV PR) , the aspartic protease of human immunodefi-
ciency virus (HIV-1 PR), and the human cyclin-dependent protein kinase 2 (CDK2).19 Our results
indicate that QMLIECE is superior to LIECE when the inhibitor/protein complexes have highly
variable charge charge interactions, as in the case of 44 peptidic inhibitors of WNV PR, because
of the variable polarization effects (Figure 2) which are captured only by QMLIECE (Figure 3).
Localized molecular orbital (LMO) theory is an LSQM approach in which occupied-virtual
interactions involving distant LMOs are neglected, i.e., only density matrix and energies of LMOs
that belong to a limited number of atoms need to be calculated.28 Used as a scoring function in
virtual screening, however, LMO theory is still not fast enough for evaluating all poses of small
molecules generated by docking. Therefore, Vasilyev and Bliznyuk, performed QM implemented
in MOZYME28 based on LMOs only for the 10 – 100 top binders predicted by simplified scoring
functions.29 By comparing the results with and without solvation they pointed out that although
QM was able to provide more accurate enthalpy values, the solvation model needed to be improved.
Anikin and coworker developed another linear-scaling semi-empirical algorithm based on LMOs
named LocalSCF.30 The method resolves the self-consistent field task through the finite atomic ex-
pansion of weakly nonorthogonal localized molecular orbitals. The inverse overlap matrix arising
from the nonorthogonality of the localized orbitals is approximated by preserving the first-order
perturbation term and applying the second-order correction by means of a penalty function. Fur-
thermore, for very large systems (> 104 atoms) the performance of LocalSCF is more efficient in
CPU time and memory consumption than MOZYME with the help of the fast multipole method.31
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Figure 1: D&C protocol15 for calculation of QM interaction energy between a protein and a small
molecule (ligand). The interaction energy between a protein with m residues and the ligand is
decomposed into
Eligand-protein = Eligand-A1C1 +Eligand-N2A2C2 + . . .+Eligand-Nm−1Am−1Cm−1 +Eligand-NmAm
−Eligand-N2C1 −Eligand-N3C2 − . . .−Eligand-NmCm−1
where Ni and Ci are N terminal and C terminal cap, respectively, of residue Ai. The fragments
with blue names are protein residues with conjugate caps,17 while the ones with red names are
pure “caps” that have to be subtracted to remove the duplication in energy calculation.19 This
figure is reprinted from Ref. 19 with permission of ACS.
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Figure 2: Polarization of protein atoms due to inhibitor binding: WNV PR, whose carbons are
in green, in complex with a peptidic inhibitor, whose carbons are in cyan. The polarized charges
were calculated by subtracting SCF atomic charges before binding from that after binding, using
the D&C protocol (see Figure 1).15 The protein surface was rendered with the blue-white-red
spectrum according to polarized charges of atoms. The blue color on the surface denotes atomic
partial charges that become more positive upon binding, while red color means more negative
atomic charges upon binding, and white color indicates atomic charges which do not change upon
binding.
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Figure 3: Comparison of the calculated (QMLIECE filled symbols, LIECE empty symbols) versus
experimental binding free energies for 44 WNV PR22–24 (top left), 24 HIV-1 PR25 (top right), and
73 CDK226,27 (bottom) inhibitors. The experimental data are fitted with two-parameter models for
WNV PR, three-parameter models for HIV-1 PR, and two-parameter models for CDK2. Digit in
parentheses is the total charge of the inhibitor. This figure is reprinted from Ref.19 with permission
of ACS.
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QM/MM
The computational procedures based on QM/MM (see also the review article by J. Gascon at page
nnn) combine the strengths of both QM (accuracy) and molecular mechanics (MM) (efficiency)
methods, and are widely employed to model chemical reactions and other electronic processes in
biomolecular systems.32–42 QM/MM can be used for preparing the structures of small molecules
and proteins, such as optimizing the binding poses obtained from docking,43 and refining the ge-
ometries of enzyme active sites obtained from a harmonically restrained minimization with MM,44
or X-ray structures.45 It has been suggested that within the drug discovery process QM/MM is
valuable for (1) helping the interpretation of poorly resolved electron density,45 (2) probing the de-
tails of the interactions within enzymes active sites,46 and (3) investigating the effects of different
substituents on the binding mode or in the assessment of alternate scaffolds.47
QM/MM is also very useful in describing the process of charge polarization and electron trans-
fer, which is not possible by classical FF methods. Anisimov and coworkers used a QM/MM
docking approach based on variational finite localized molecular orbital approximation to speed
up conventional QM,30,31 which took explicitly into account the effects of charge polarization and
intermolecular charge transfer.48 Gentilucci et al. carried out QM/MM calculation to investigate
the binding mode into the M-opioid receptor and the electronic properties of an atypical agonist,
the cyclic peptide c[YpwFG] which contains aromatic side chains.43 In their research the highly
favorable dipole-dipole interaction between the protein and the peptide agonist indicates that lig-
and polarization induced by the protein environment contribute noteworthily to the overall binding
energy. Gao and coworkers used docking, molecular dynamics (MD), and QM/MM methods to
study the reaction dynamics between pyrimidine nucleoside phosphorylase and a substrate.49 Their
results show that catalysis involved residues stabilize the uridine in a high-energy conformation by
electrostatic interactions and the activation of phosphorolytic catalysis stems from polarization ef-
fects. As mentioned above, QM is also appropriate to describe electron transfer. Blumberger and
coworkers applied QM/MM to calculate the free energy profile for peptide bond cleavage.50 Zheng
and coworkers developed a QM/MM based approach for in silico screening of transition states of
the enzymatic reaction and calculated the activation energy.51 By this approach they designed a
human butyrylcholinesterase mutant with a 2000 fold improved catalytic efficiency for therapeu-
8
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tic use as an exogenous enzyme in humans to treat cocaine overdose and addiction. Wallrapp
and coworkers presented docking and QM/MM studies for the electron transfer pathway between
cytochrome P-450 camphor and putidaredoxin.52
QM/MM is a powerful instrument of parameterization of FFs for the system containing struc-
tural motifs not adequately described by empirical FFs, such as diverse drug-like molecules,53 and
metal-containing system.54 QM/MM can also be used for incorporating polarization effects into a
FF, which enables the qualitative improvement in constructing patterns of hydrogen bonds of the
docked ligand, water structures and dynamics.55
QM Simulation
QM simulation is a useful tool for unraveling the mechanism of reactions.56 In the drug design field
which involves biological macromolecules, QM simulation is often working with the classical MD
simulation.40,57 To explain the catalytic pathway of metalloenzyme farnesyltransferase (FTase),
Ho and coworkers exploited the Car-Parrinello MD58 version of QM(B3LYP density functional
theory (DFT))/MM(Amber FF59) dynamics. Their results might be helpful in designing selective
inhibitors of FTase, given the proposed mechanism of the FTase reaction and the inhibition by
fluorine substituents of farnesyl diphosphate substrate.60
QM combined with classical MD is also useful for improving accuracy of interaction energy
and sampling of conformational space (see review article by J. Gascon at page nnn). Feenstra and
coworkers used semi-empirical QM to calculate activation energy barriers, and compare substrate
activation barriers at different locations from MD simulations in the enzyme.61 Alves and cowork-
ers explained the viral resistance of diketo acids (DKAs) to the integrase of human immunodefi-
ciency virus (HIV-1 IN) N155S mutant by QM/MM MD simulation.62 Their decomposition anal-
ysis of energy terms shows that there is a strong interaction between the Lys159, Lys156, Asn155,
and Mg 2+ cation and the DKA inhibitor with complex electrostatic interactions. QM/MM can be
used in free energy perturbation (FEP) method. QM/MM FEP was applied to calculate the relative
solvation free energies for a diverse set of small molecules (root mean square deviation (RMSD))
from experimental data < 1.02 kJ·mol−1).53 Using the same method, the > 2000 fold decrease
in the affinity for fructose-1,6-bisphosphatase of an adenosine monophosphate (AMP) analogue
9
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(phosphonate 4) compared with AMP was explained by the absence of hydrogen bonds and the
loss of the electrostatic interactions,63 which were well described by the QM method.64 Similarly
Khandelwal and coworkers reported that QM/MM calculated energies for the time averaged struc-
tures from MD simulations were able to distinguish subtle differences in binding affinities of only
one order of magnitude (Figure 4).65,66 These methods, however, are very time-consuming, and
therefore are not applicable for in silico high throughput screening at present.
 
Method r
2 
FlexX docking 0.044 
QM/MM minimization 0.504 
MD simulation 0.760 
MD + QM/MM energy 0.900 
Figure 4: Correlations between experimental and calculated inhibition potencies of hydroxamates
vs MMP-9 as obtained by FlexX docking with the zinc-binding-based selection of modes (green),
QM/MM minimization (blue), MD simulation with constrained zinc bonds (red), and by QM/MM
energy calculations for the time-averaged structures from MD simulation (black).65,66 This figure
is reprinted from Ref. 65 with permission of ACS.
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Protonation states
The rapid growth of the number of protein structures determined by X-ray crystallography calls
for robust methods for determining hydrogen positions, in particular for active site residues in
enzymes.35,36,67 Explicit hydrogen atoms are required for most of the structure based drug de-
sign methods,68 e.g., all-atom MM, MD, docking, and electrostatic calculations. A recent study
reaffirms that the protonation state in the active site influences the ability of scoring methods to de-
termine the native binding pose.69 Although other classical methods, e.g., MD67 and MM/Poisson-
Boltzmann (PB) surface area,70 can be used for determining the position of hydrogen atoms, the
prediction of protonation states should be more robust by means of QM because protonation is
related to the formation of the covalent bond between the hydrogen and heavy atom.
There are several studies on the determination of protonation states of protease, e.g., β -secretase
(BACE),71–74 plasmepsin,67 and HIV-1 PR.69,75 Which of the two aspartates in the catalytic dyad
of BACE (Asp32 or Asp228) is protonated is likely to depend on the presence and type of in-
hibitor.71,72,76 Rajamani and coworkers used a LSQM method and the finite-difference PB method
to determine the protonation state and proton location in the presence and absence of an inhibitor.72
They performed structural optimization in the region surrounding the catalytic dyad. Their calcula-
tion favors the monoprotonated state of Asp228 in presence of the hydroxyethylene based inhibitor
and di-deprotonated state for the apo enzyme. Yu and coworkers applied the QM/MM to further
refine the X-ray structure of BACE, and observed an energetically favored monoprotonated con-
figuration of Asp32 by fitting eight refined structures of BACE and an inhibitor to the observed
electron density.74
Determination of protonation states of metal-binding sites poses challenges on classical meth-
ods.77,78 Lin and Lim used a combination of QM and continuum dielectric methods to compute
the free energies for deprotonating a Zn-bound imidazole/water in various zinc complexes.79 They
found that the protonation state of the His in the Zn-binding site depends on the solvent accessi-
bility of metal-binding site and Lewis acid ability of the zinc atom. They also suggested that it is
critical for the QM region to include not only the metal’s first-shell interactions, but also the sec-
ond shell in QM/MM modeling of metal-binding sites of metalloproteins.79,80 A comprehensive
review of Kamerlin and coworkers summarizes the progresses in ab initio QM/MM free-energy
11
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simulations of electrostatic energies in proteins.40 Their accelerated QM/MM method, which uses
an updated mean charge distribution and a classical reference potential, was benchmarked on the
pKa of titratable side chains. For Asp3 in the bovine pancreatic trypsin inhibitor they obtained the
deviation of ∼ 1 pKa unit (1 kcal·mol−1). For Lys102 in T4-lysozyme mutant the deviation was
2.4 pKa unit (∼ 3 kcal·mol−1). The protonation state of Lys102 may affect the conformation of
the protein, since it is deeply buried in the hydrophobic surface. Therefore there is much larger
likelihood to attain significant errors in calculation of pKa of its side chain.81 Compared to the
7 kcal·mol−1 energy difference required for catalysis, an error of 3 kcal·mol−1 may be acceptable
to determine the main energetic contribution to the reaction.
Cation-pi and pi-pi interactions
Cation-pi and pi-pi stacking interactions play a fundamental role in chemical and biological recog-
nition.82 Classical FFs sometimes fail to describe these interactions because of the lack of charge
delocalization in fixed-charge models or the particular FF parameters. Even HF methods have lim-
itations in capturing pi-interactions because of incompleteness of electronic correlation.83,84 Villar
and coworkers analyzed whether ligand-protein binding enthalpies evaluated by semi-empirical
Austin Model 1 (AM1) are sufficient for use in the rational design of new drugs by comparing
with B3LYP DFT, and MP2 method.85 They pointed out that with the exception of cation-pi in-
teractions the enthalpies calculated by AM1 correlated well with that by counterpoise-corrected
MP2/6-31G(d). However, the structures calculated by AM1 and DFT do not correlated with that
calculated by MP2 consistently. Wu and McMahon applied DFT and MP2 to optimize the struc-
tures of the most stable isomers of protonated Tyr and ammonia or methylamine and to calculate
the enhancement of binding energies due to cation-pi interactions. Møller-Plesset perturbation
and coupled-cluster methods show that dispersive forces and electrostatic and exchange-repulsion
forces play the primary stabilizing role in pi-stacked complexes.84,86,87 High-level ab initio cal-
culations, including extrapolation to the MP2 basis set limit and inclusion of a CCSD(T) cor-
rection, show that T-shaped and parallel-displaced configurations are virtually isoenergetic in gas
phase, with binding energies of −11.46 and −11.63 kJ·mol−1 respectively, whereas the sandwich
structure is less stable at −7.57 kJ·mol−1 (Figure 5),84 and substituted benzene dimers bind more
12
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strongly than unsubstituted benzene.88 Hobza and coworkers suggested to model the pi-pi stacking
interactions by MP2 with a medium-sized basis set with a more diffuse polarization function, i.e.,
MP2/6 31G*(0.25) where exponents of d polarization functions are changed into more diffuse 0.25
from 0.8 used in the standard 6-31G* basis.89–92 Because of its computational efficiency, DFT has
been used by several groups to describe pi-stacking interactions.93–97 To attain predicting power
similar to high-level ab initio methods, some researchers have combined HF theory and DFT, and
using modest basis sets have reproduced the potential energy surface of higher level calculations
for a number of instances of pi-stacking.98–100
Using QM to calculate molecular properties
It has long been recognized that if one could accurately evaluate the standard free energy change
of complexation of biologically active molecules, it would be possible both to gain a deeper under-
standing of molecular recognition in biology, and to shed light onto the first principles design of
pharmaceuticals and other compounds.101 The currently available computer power does not allow
highly accurate QM calculations of free energies, particularly for proteins and ligands in solution.
Moreover, usage of QM methods in high-throughput docking is prohibitive. Therefore QM is
more suitable to derive models for prediction rather than for the direct evaluation of binding free
energies. Classical FFs and QSAR are examples of compromises between accuracy and efficiency.
QM derived FFs
Due to the large chemical space of molecules, FFs do not include all the parameters required for
describing drug-like molecules.102 QM is being used routinely in optimizing geometries, fitting
the torsion parameters, and deriving atomic charges for proteins,103 DNA,104 and in particular
small molecules.105–108 Spiegel and coworkers developed a new set of FF parameters of platinated
moiety via a force matching procedure of the classical forces to ab initio forces obtained from
QM/MM trajectories, and extended the classical MD simulation to describe slow converging re-
arrangement of dinuclear Pt compounds and DNA duplex.109 Sugiyama and coworkers used DFT
calculated partial charges and FF parameters for the atoms near the active site, which are usually
significantly polarized, and metal atoms for which FF parameters are not available.110
13
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(a) (b)
(c)
Figure 5: (a) Sandwich, (b) T-shaped, and (c) parallel-displaced configurations of the benzene
dimer.84,88
14
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Multipole expansion (ME) is often used in the representation of the molecular electrostatic
potential.30,111–113 To account for the effects of charge penetration, the point charges, dipoles,
quadrupoles, and octupoles in ME model need to be damped. The damping strategies are particular
crucial for short-range energies. For example, damping strategies have to be used when ME is
applied on calculation of electrostatic potentials or electric fields on van der Waals (vdW) or solvent
accessible surface of a molecule.114 Werneck and coworkers suggested a general methodology
to optimize the damping functions with the ab initio (HF/6-31G** and 6-31G**+) electrostatic
potential.115
QM-derived partial charges
In the molecular simulations with fixed charge models, the method used to derive partial charges in-
fluences the computed physical properties and subsequent docking and scoring significantly.116,117
Mobley and coworker compared the hydration free energies of small molecules, whose partial
charges are assigned according to different levels of QM, including AM1, HF, DFT, and MP2, by
explicit water MD simulations.118 They found that AM1 bond charge correction method119 for
computing charges works almost as well as any of the more computationally expensive ab initio
method. Fischer et al. compared FF-based scoring functions with QM-based scoring functions
by computing binding free energies of eleven ligands to the human estrogen receptor subtype α
(ERα) and four ligands to the human retinoic acid receptor of isotype γ .120 They found that the
improvement for the complexs with the ERα receptor stemmed from applying classical electro-
static models partial charges derived by fragment molecular orbital (FMO).121 Illingworth and
coworkers implemented QM/MM derived induced charges into a classical framework, redocked
12 difficult protein-ligand complexes with AutoDock,122 and found that there was no significant
improvement in RMSD of the lowest energy structure against the crystal structure but an incre-
ment of the largest cluster size.123 Pasquini and coworkers explained different binding affinities
of similar compounds to HIV-1 IN by calculating the partial charges of these compounds and at-
tributed the difference to a poor interaction of the molecules with the divalent metal ions of the
active site due to the electron-withdrawing effect.7 Instead of using fixed and point-charge model,
Wang and coworkers calculated solvation free energies of 31 small neutral molecules from QM
15
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charge density and continuum dielectric theory (finite-difference PB equation).124 The QM and
PB equations were solved self-consistently until both the charge and reaction field converged.
The calculations took into account polarized electronic wave function asymmetric distortion, and
spreading out of the electron cloud. In particular, when the solute is treated by QM, part of its
electron density penetrates into the solvent. The experimentally measured solvation free energies
of these molecules spanned a range of 25 kcal·mol−1. The authors reported root mean square error
of only 1.3 kcal·mol−1 upon tuning a single parameter to shift the calculated values.
QM descriptors in QSAR/QSPR models
The information provided by QM is more accurate than FFs, therefore more robust QSAR models
and/or QSPR models are expected with QM descriptors.125 Partial charges are the most common
descriptors in QSAR/QSPR models due to their simplicity and informative content. Occhiato and
coworkers employed atomic partial charges derived from DFT electrostatic potential in a CoMFA
model, with which they designed new 5α-reductase 1 inhibitors.126 Lepp and Chuman applied
LocalSCF calculated atomic charges to build a QSAR model to predict Michaelis-Menten con-
stants, and attained better correlation than classical QSAR descriptors.127 Wan et al. found that
the net charge of the atoms and polarizability correlate with biological activity.128 Furthermore,
they reported that the predictive power of QSAR models derived from DFT charges is higher than
from semi-empirical PM3 charges. Besides partial charges, other QM descriptors are commonly
used to build QSAR/QSPR models. Yamagami and coworkers used various quantum chemical
descriptors, e.g., frontier energy and frontier electron density, which are powerful for describing
chemical reactivity.129 Their CoMFA method shows that the antimutagenic activities are increased
by electron-withdrawing substituents and also by hydrogen-bonding between 2-hydroxy group and
the receptor. Singh and coworkers developed a QSAR model of derivatives of testosterone with
several QM parameters, e.g., absolute hardness and electronegativity.130 Pasha and coworkers de-
rived QSAR models utilizing various QM descriptors to analyze the factors affecting inhibitory
potency for a series of analogues of the MK886 inhibitor of microsomal prostaglandin E2 synthase-
1.131 These QM models indicate that the steric properties, as well as electrostatic and hydrophobic
interactions are relevant to the inhibitory potency.
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Molecular quantum similarity
Molecular similarity measures have been used in CADD since more than 15 years.132 Malde and
coworkers have investigated boron analogs of natural peptides by QM to find the secondary struc-
tural preferences and the impact on stability of different substitutions on boron.133–135 Recently
they have shown that the B(OH)−NH isostere is an interesting surrogate for the peptide bond
because of the similar geometry and barrier for rotation around the backbone dihedral angle ω ,
as well as stability to proteolytic enzymes.136 Carbó et al. measured the similarity of electron
density calculated by QM, and developed a novel QSAR descriptor named molecular quantum
similarity measures (MQSM).137–144 The MQSM relies on the first order electronic density func-
tion as molecular descriptor. Before comparing the similarities of electronic density functions,
approximated functions145,146 and a maximization algorithm are needed to obtain optimal molec-
ular superposition.147 The MQSM was then used to predict the toxicity148,149 and to describe
the substituent effect in an aromatic series traditionally described by empirical Hammett equa-
tion.144,150 MQSM also can be applied for classification of molecules using dendrograms.151 A
further development of MQSM is quantum topological molecular similarity (QTMS),152 which is
based on the definition of distances between molecules in bond critical point space.153,154 QTMS
is very useful to describe pKa of molecules as QSAR descriptors.155,156 Singh et al. suggested the
connection between QTMS and relative bond dissociation enthalpies, and attained good QSAR.157
Hemmateenejad and Mohajeri used QTMS indices for describing the quantitative effects of molec-
ular electronic environments on the O-methylation kinetic of substituted phenols.158 Their results
revealed that the rate constant of esterification of phenols is highly influenced by the electronic
properties of the C2−C1−O−H fragment of the parent molecule, which can be considered as fron-
tier bonds in the O-methylation reaction. As shown in these examples, the effects of substitutions
are related to the electron density of the bond connecting the scaffolds and the substituents, such
that molecular quantum similarity is suitable for studying substitutive effects.
Variational particle number approach for molecular design
Chemical space is the high-dimensional molecular space spanned by the astronomical number of
accessible chemical structures. How to sample the chemical space efficiently is always a difficult
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problem in de novo drug design. In general terms, compound design efforts usually attempt a
mapping of a given molecular system to the observable of interest. However in structure-based
drug design, the inverse question applies, i.e., which modification of a given compound will re-
sult in a desired molecular property. Two independent research groups have recently addressed
this question. Lilienfeld and coworkers developed an approach that can explore chemical space
in a less heuristic manner by extending the conceptual DFT by the chemical potential for nuclei
(alchemical potential).159 With their approach, they modified a peptidic inhibitor of an anticancer
target (human X-chromosome linked inhibitor-of-apoptosis-proteins) into a nonpeptidic inhibitor
by optimizing the interaction energy between the inhibitor and the target. Almost at the same time,
Wang and coworkers optimized molecular polarizability and hyperpolarizability using a similar
method. The main idea of these methods is mapping the discrete chemical structures onto a con-
tinuous hypersurface (Figure 6). In this case, enumerating the astronomical number of discrete
chemical structures can be avoided by a systematic optimization of parameters introduced in the
mapping procedure. Up to now, these methods are merely applied for optimizing several molecular
properties e.g., polarizability and hyperpolarizability, which can be calculated by QM straightfor-
wardly.160–166 QSAR/QSPR models may bridge the gap between the properties calculated directly
by QM and those that are useful for drug discovery, e.g., high binding affinity and selectivity to
the target, good pharmacokinetics and pharmacodynamics, and low toxicity, so that the variational
particle number approach might become a routine of structure-based drug design.
Conclusion and outlook
Several QM-based methods already play an important role in many phases of CADD, and will have
a stronger impact in the future because of the ever growing computing power and development of
efficient algorithms. The compromise between accuracy and efficiency is a perpetual issue in the
applications of QM methods. It is important to select the most appropriate technique at each phase
of drug development, and QM methods should be selected only if there is a real advantage with
respect to the classical approaches. The initial phase of CADD, e.g., high-throughput docking,
which is useful to identify hit compounds,168 requires full sampling of conformations of the small
molecules within the protein binding site. Such extensive sampling calls for approximated energy
18
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Figure 6: Schematic representation of optimization of molecular properties by a linear combina-
tion of atomic potentials. Bar heights represent electronic polarizabilities for candidate structures.
The optimization of the property is performed on the smooth (hyper)surface (only two degrees of
freedom are denoted). Establishing a well behaved property surface that interpolates among the
realizable molecules is a key aspect of the variational particle number approach.167 This figure is
reprinted from Ref. 167 with permission of ACS.
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functions and predicted properties thereof, which are usually calculated by classical FF methods
or fast semi-empirical QM methods. In the subsequent phase, hits have to be optimized to leads
which does not require extensive sampling but high accuracy because of the small differences in
the binding free energy. Therefore QM methods should be applied on the hits to shed light on the
energetics of binding. The QM methods are particularly important to capture charge transfer and
polarization effects, which are usually pronounced in systems containing metal atoms or charged
groups, and/or dispersion forces which play a significant role in the interactions of conjugated pi
systems. Importantly, before starting CADD it is necessary to evaluate the status of the project,
which in turn dictates the number and diversity of molecules to be evaluated and the demand of
accuracy, and to select the most appropriate approach accordingly.
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